
BLTE Stock Forecast & Price Target
BLTE Analyst Ratings
Bulls say
Belite Bio Inc has received positive interim Phase 3 results for its lead asset tinlarebant, which may heighten interest in potential treatment options for both Stargardt disease and dry age-related macular degeneration (AMD). The company is expected to drive share appreciation in the upcoming 12-18 months, backed by updates from its ongoing Phase 3 programs and an increase in sample size for the PHOENIX trial. Additionally, tinlarebant's recognition through multiple designations, including fast track and orphan drug status, underscores its promising clinical profile and potential market value, leading to an updated DCF-based equity value estimate significantly higher than previous forecasts.
Bears say
Belite Bio Inc has consistently reported operating losses since its inception, with a net loss of $36.1 million in 2024, leading to concerns about the company's potential for profitability in the near future. The dependence on reimbursement policies, which may be jeopardized by economic factors such as austerity measures and consumer financial health, adds additional risk to the firm's revenue projections. Moreover, the uncertainty surrounding regulatory outcomes and reimbursement frameworks further heightens the volatility and risk associated with Belite Bio's stock.
This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
BLTE Analyst Forecast & Price Prediction
Start investing in BLTE
Order type
Buy in
Order amount
Est. shares
0 shares